Key result
Darbepoetin alfa fails to reduce death or HF hospitalization vs placebo in anemic heart failure.
Why the study?
Anaemia is common in HF patients and associated with worse outcomes, but it is unclear whether treatment with erythropoiesis-stimulating agents improves morbidity and mortality.
Hazard Ratio: 1.01 (95% CI 0.9–1.13)
p-value: p=0.87
No takes yet. Share an insight, caveat, or question.
Darbepoetin alfa should not be used to improve outcomes in heart failure with anaemia; confirms lack of benefit and closes this treatment approach.
Kleijn et al. (2013) conducted an editorial in Heart failure and anaemia (n=2,278). Darbepoetin alfa vs. Placebo was evaluated on Composite of time to death from any cause or first hospital admission for worsening heart failure (HR 1.01, 95% CI 0.90-1.13, p=0.87). Darbepoetin alfa did not reduce the composite of all-cause death or heart failure hospitalization compared with placebo in patients with heart failure and anaemia (HR 1.01; 95% CI 0.90-1.13; P=0.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: